Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 3
2004 4
2005 4
2006 2
2007 4
2008 8
2009 3
2010 2
2011 1
2012 3
2013 5
2017 2
2018 2
2019 2
2020 4
2021 4
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Results by year

Filters applied: . Clear all
Page 1
Adaptive study design to assess effect of TRPV4 inhibition in patients with chronic cough.
Ludbrook VJ, Hanrott KE, Kreindler JL, Marks-Konczalik JE, Bird NP, Hewens DA, Beerahee M, Behm DJ, Morice A, McGarvey L, Parker SM, Birring SS, Smith J. Ludbrook VJ, et al. Among authors: behm dj. ERJ Open Res. 2021 Aug 2;7(3):00269-2021. doi: 10.1183/23120541.00269-2021. eCollection 2021 Jul. ERJ Open Res. 2021. PMID: 34350286 Free PMC article.
TRPV4 antagonists: a patent review (2015-2020).
Lawhorn BG, Brnardic EJ, Behm DJ. Lawhorn BG, et al. Among authors: behm dj. Expert Opin Ther Pat. 2021 Sep;31(9):773-784. doi: 10.1080/13543776.2021.1903432. Epub 2021 Mar 24. Expert Opin Ther Pat. 2021. PMID: 33724130 Review.
Identification of a Human Whole Blood-Based Endothelial Cell Impedance Assay for Assessing Clinical Transient Receptor Potential Vanilloid 4 Target Engagement Ex Vivo.
Xu X, Goyal N, Costell MH, Roethke T, James CH, Thorneloe KS, Patterson J, Stoy P, Goodman K, Sprecher DL, Behm DJ. Xu X, et al. Among authors: behm dj. J Pharmacol Exp Ther. 2021 Mar;376(3):436-443. doi: 10.1124/jpet.120.000307. Epub 2020 Dec 29. J Pharmacol Exp Ther. 2021. PMID: 33376150
Investigating the effect of TRPV4 inhibition on pulmonary-vascular barrier permeability following segmental endotoxin challenge.
Mole S, Harry A, Fowler A, Hotee S, Warburton J, Waite S, Beerahee M, Behm DJ, Badorrek P, Müller M, Faulenbach C, Lazaar AL, Hohlfeld JM. Mole S, et al. Among authors: behm dj. Pulm Pharmacol Ther. 2020 Oct;64:101977. doi: 10.1016/j.pupt.2020.101977. Epub 2020 Nov 13. Pulm Pharmacol Ther. 2020. PMID: 33189900 Clinical Trial.
Recent advances in TRPV4 agonists and antagonists.
Lawhorn BG, Brnardic EJ, Behm DJ. Lawhorn BG, et al. Among authors: behm dj. Bioorg Med Chem Lett. 2020 Apr 15;30(8):127022. doi: 10.1016/j.bmcl.2020.127022. Epub 2020 Feb 8. Bioorg Med Chem Lett. 2020. PMID: 32063431 Review.
Discovery of GSK3527497: A Candidate for the Inhibition of Transient Receptor Potential Vanilloid-4 (TRPV4).
Brooks CA, Barton LS, Behm DJ, Brnardic EJ, Costell MH, Holt DA, Jolivette LJ, Matthews JM, McAtee JJ, McCleland BW, Patterson JR, Pero JE, Rivero RA, Roethke TJ, Sanchez RM, Shenje R, Terrell LR, Lawhorn BG. Brooks CA, et al. Among authors: behm dj. J Med Chem. 2019 Oct 24;62(20):9270-9280. doi: 10.1021/acs.jmedchem.9b01247. Epub 2019 Oct 9. J Med Chem. 2019. PMID: 31532662
51 results